Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
Trial Parameters
Brief Summary
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: * Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? * Is IM ketamine safe and tolerable among patients with MeUD? Participants will: * Receive 3 monitored doses of IM ketamine * Have 3 preparation and 4 integration psychotherapy visits * Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention
Eligibility Criteria
Inclusion Criteria: * Age 18-69 * Moderate or severe methamphetamine use disorder * Interest in reducing or stopping methamphetamine use * Insured by MediCal, MediCare, or Healthy San Francisco * Used methamphetamine ≥7 out of the 30 days prior to screening OR enrolled in a residential drug treatment program * Have a diagnosis of HIV OR taken PrEP over the last 90 days OR engaged in ≥1 risk behavior for HIV acquisition/transmission over the last 90 days (i.e., anal sex under the influence of methamphetamine, condomless sex with a partner of serodiscordant or unknown HIV status, or any shared use of injection drug supplies) * English speaking * Permanently housed for ≥30 days OR enrolled in residential drug treatment for ≥5 days * Have a text-capable cell phone or access to email (if not enrolled in residential treatment) * Able and willing to provide informed consent and adhere to visit schedule * If necessary, willing to be contacted on a daily basis by one of the therapists for 7 day